US 10682339
Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
granted A61KA61K31/4184A61K45/06
Quick answer
US patent 10682339 (Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same) held by The Board of Regents of the University of Texas System expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/4184, A61K45/06